Covestro Begins Local Medical-Grade TPU Production in Taiwan
ECONOMY & POLICY

Covestro Begins Local Medical-Grade TPU Production in Taiwan

Covestro has launched localised production of medical-grade Thermoplastic Polyurethane (TPU) at its Changhua site in Taiwan, marking its first such facility in the Asia Pacific region. The site, now qualified for medical-grade TPU manufacturing, will produce Desmopan® Rx grades, enabling faster and more secure regional supply for high-performance medical applications.

This is Covestro’s second global site after New Martinsville, North America, to manufacture medical-grade TPU. The move reflects rising demand driven by improved healthcare standards and an ageing global population.

Meeting Global Standards, Serving Regional Needs

Manufactured in line with Good Manufacturing Practice (GMP) guidelines, Desmopan® Rx grades meet international medical standards including ISO 10993 and China’s YY/T 1557, ensuring biocompatibility and minimised contamination risks. Free from added plasticisers, the TPU grades offer low extractables and are compatible with multiple sterilisation methods.

Dr Frank Yang, Head of Asia-Pacific Innovation TPU at Covestro, stated: “Our Desmopan® Rx grades meet established medical industry standards. This production shift ensures product safety, compliance, and timely delivery for regulated Asian markets.”

Designed for Advanced Medical Use

Desmopan® Rx TPUs are tailored for a wide range of medical devices, including tubing, catheters, connectors, housings, endoscopes, and wearable devices. Their use spans surgical procedures, drug delivery, dialysis, wound care, and more.

The material’s benefits include:

  • Biocompatibility for patient-contact use
  • High clarity for medical observation
  • Kink resistance for uninterrupted fluid flow
  • Excellent chemical and abrasion resistance
  • Superior flexibility and dimensional stability

Additionally, Desmopan® Rx is suitable for melt-blown medical nonwovens used in drapes, gowns, sterile packaging, and PPE, offering strong performance while complying with medical waste regulations.

Strengthening Regional Infrastructure

The Changhua facility complements Covestro’s Zhuhai production base and its new application development centre in Guangzhou, enhancing local innovation and delivery capabilities. Kevin Ho, Head of Sales and Market Development TPU Asia Pacific, noted, “With Changhua online, we can now shorten lead times and improve supply reliability for the region.”

Covestro is showcasing the Desmopan® Rx range at Booth N5E24 during CPHI & PMEC China, running through 26 June at the Shanghai New International Expo Center.

Covestro has launched localised production of medical-grade Thermoplastic Polyurethane (TPU) at its Changhua site in Taiwan, marking its first such facility in the Asia Pacific region. The site, now qualified for medical-grade TPU manufacturing, will produce Desmopan® Rx grades, enabling faster and more secure regional supply for high-performance medical applications.This is Covestro’s second global site after New Martinsville, North America, to manufacture medical-grade TPU. The move reflects rising demand driven by improved healthcare standards and an ageing global population.Meeting Global Standards, Serving Regional NeedsManufactured in line with Good Manufacturing Practice (GMP) guidelines, Desmopan® Rx grades meet international medical standards including ISO 10993 and China’s YY/T 1557, ensuring biocompatibility and minimised contamination risks. Free from added plasticisers, the TPU grades offer low extractables and are compatible with multiple sterilisation methods.Dr Frank Yang, Head of Asia-Pacific Innovation TPU at Covestro, stated: “Our Desmopan® Rx grades meet established medical industry standards. This production shift ensures product safety, compliance, and timely delivery for regulated Asian markets.”Designed for Advanced Medical UseDesmopan® Rx TPUs are tailored for a wide range of medical devices, including tubing, catheters, connectors, housings, endoscopes, and wearable devices. Their use spans surgical procedures, drug delivery, dialysis, wound care, and more.The material’s benefits include:Biocompatibility for patient-contact useHigh clarity for medical observationKink resistance for uninterrupted fluid flowExcellent chemical and abrasion resistanceSuperior flexibility and dimensional stabilityAdditionally, Desmopan® Rx is suitable for melt-blown medical nonwovens used in drapes, gowns, sterile packaging, and PPE, offering strong performance while complying with medical waste regulations.Strengthening Regional InfrastructureThe Changhua facility complements Covestro’s Zhuhai production base and its new application development centre in Guangzhou, enhancing local innovation and delivery capabilities. Kevin Ho, Head of Sales and Market Development TPU Asia Pacific, noted, “With Changhua online, we can now shorten lead times and improve supply reliability for the region.”Covestro is showcasing the Desmopan® Rx range at Booth N5E24 during CPHI & PMEC China, running through 26 June at the Shanghai New International Expo Center.

Next Story
Infrastructure Transport

MMRDA advances 250 m on Orange Gate–Marine Drive tunnel

The Mumbai Metropolitan Region Development Authority (MMRDA) has completed 250 m of underground tunnelling for the Orange Gate–Marine Drive Urban Road Tunnel using India’s largest slurry shield tunnel boring machine (TBM) deployed for an urban road project.The project involves twin tunnels extending over 7 km beneath critical transport corridors, including Central Railway, Western Railway and Metro Line 3. The work requires high-precision engineering to navigate densely developed urban infrastructure.Once completed, the tunnel is expected to reduce travel time between Orange Gate and Marin..

Next Story
Infrastructure Urban

Hindustan Zinc Pays Rs 188.46 Billion in FY26

Hindustan Zinc contributed Rs 188.46 billion to the public exchequer in FY 2025-26, according to its 9th Tax Transparency Report. The contribution, equivalent to 46 per cent of the company’s revenue, included direct and indirect taxes, government royalties, dividends to the Government of India, withholding taxes and other statutory levies.The company’s five-year cumulative contribution to the exchequer stood at Rs 915.72 billion. In FY26, Hindustan Zinc reported revenue of Rs 408.44 billion, EBITDA of Rs 221.62 billion and profit after tax of Rs 138.32 billion. It also achieved its highest..

Next Story
Infrastructure Urban

World of Concrete India 2026 Opens in Mumbai

Informa Markets in India will host the 12th edition of World of Concrete India 2026 from 3–5 June 2026 at the Bombay Exhibition Centre, Mumbai. The specialised B2B exhibition will bring together manufacturers, suppliers, contractors, developers, architects, consultants, infrastructure companies, project leaders and government stakeholders.The event is expected to feature over 350 brands and more than 18,000 trade professionals. It will cover concrete and cement, dry mortar, precast technologies, formwork, construction chemicals, industrial and commercial flooring, scaffolding, safety solutio..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement